{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:37:24Z","timestamp":1761975444406,"version":"build-2065373602"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00520-013-1911-7","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T08:03:46Z","timestamp":1375257826000},"page":"2925-2932","source":"Crossref","is-referenced-by-count":83,"title":["Clinical experience with Zarzio\u00ae in Europe: what have we learned?"],"prefix":"10.1007","volume":"21","author":[{"given":"Pere","family":"Gasc\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Verpoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Sofia","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nello","family":"Salesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Muenzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"1911_CR1","unstructured":"European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor [EMEA\/CHMP\/BMWP\/31329\/2005]. European Medicines Agency, London, 2006. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003955.pdf [Accessed 24 August 2012]"},{"key":"1911_CR2","unstructured":"European Union. Commission Directive 2003\/63\/EC, amending Directive 2001\/83\/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2003:159:0046:0094:EN:PDF [Accessed 24 August 2012]"},{"key":"1911_CR3","unstructured":"European Union. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use. http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CONSLEG:2001L0083:20091005:EN:PDF [Accessed 24 August 2012]"},{"key":"1911_CR4","unstructured":"Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf [Accessed 24 August 2012]"},{"key":"1911_CR5","doi-asserted-by":"crossref","unstructured":"Gasc\u00f3n P (2012) Presently available biosimilars in hematology\u2013oncology: G-CSF. Target Oncol 7(suppl 1):S29\u2013S34","DOI":"10.1007\/s11523-011-0190-9"},{"key":"1911_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"1911_CR7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00063030-200721060-00003","volume":"21","author":"AA Genazzani","year":"2007","unstructured":"Genazzani AA, Biggio G, Caputi AP et al (2007) Biosimilar drugs: concerns and opportunities. BioDrugs 21:351\u2013356","journal-title":"BioDrugs"},{"key":"1911_CR8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/fon.10.72","volume":"6","author":"H Mellstedt","year":"2010","unstructured":"Mellstedt H (2010) Implications of the development of biosimilars for cancer treatment. Future Oncol 6:1065\u20131067","journal-title":"Future Oncol"},{"key":"1911_CR9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdm345","volume":"19","author":"H Mellstedt","year":"2008","unstructured":"Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411\u2013419","journal-title":"Ann Oncol"},{"key":"1911_CR10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0609.2010.01566.x","volume":"86","author":"D Niederwieser","year":"2011","unstructured":"Niederwieser D, Schmitz S (2011) Biosimilar agents in oncology\/haematology: from approval to practice. Eur J Haematol 86:277\u2013288","journal-title":"Eur J Haematol"},{"key":"1911_CR11","doi-asserted-by":"crossref","unstructured":"Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 2011; Suppl 4: S1\u2013S22","DOI":"10.6004\/jnccn.2011.0136"},{"key":"1911_CR12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nbt0110-28","volume":"28","author":"H Schellekens","year":"2010","unstructured":"Schellekens H, Moors E (2010) Clinical comparability and European biosimilar regulations. Nat Biotechnol 28:28\u201331","journal-title":"Nat Biotechnol"},{"key":"1911_CR13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/11585100-000000000-00000","volume":"24","author":"F S\u00f6rgel","year":"2010","unstructured":"S\u00f6rgel F, Lerch H, Lauber T (2010) Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 24:347\u2013357","journal-title":"BioDrugs"},{"key":"1911_CR14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.biologicals.2010.05.002","volume":"38","author":"A Skrlin","year":"2010","unstructured":"Skrlin A, Radic I, Vuletic M, Schwinke D, Runac D, Kusalic T, Paskvan I, Krsic M, Bratos M, Marinc S (2010) Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 38:557\u2013566","journal-title":"Biologicals"},{"key":"1911_CR15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/annonc\/mdp574","volume":"21","author":"P Gasc\u00f3n","year":"2010","unstructured":"Gasc\u00f3n P, Fuhr U, S\u00f6rgel F et al (2010) Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 21:1419\u20131429","journal-title":"Ann Oncol"},{"key":"1911_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"},{"key":"1911_CR17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O'Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"1911_CR18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00063030-200923010-00005","volume":"23","author":"H Lubenau","year":"2009","unstructured":"Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K (2009) Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 23:43\u201351","journal-title":"BioDrugs"},{"key":"1911_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5414\/CPP47275","volume":"47","author":"H Lubenau","year":"2009","unstructured":"Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, Janulionis V (2009) Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 47:275\u2013282","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1911_CR20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-8-332","volume":"8","author":"A Giglio del","year":"2008","unstructured":"del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy. BMC Cancer 8:332","journal-title":"BMC Cancer"},{"key":"1911_CR21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/JTO.0b013e3181a52964","volume":"4","author":"U Gatzemeier","year":"2009","unstructured":"Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A (2009) XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 4:736\u2013740","journal-title":"J Thorac Oncol"},{"key":"1911_CR22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/10428190902756081","volume":"50","author":"A Engert","year":"2009","unstructured":"Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 50:374\u2013379","journal-title":"Leuk Lymphoma"},{"key":"1911_CR23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00277-010-0973-6","volume":"89","author":"CF Waller","year":"2010","unstructured":"Waller CF, Bronchud M, Mair S, Challand R (2010) Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:971\u2013978","journal-title":"Ann Hematol"},{"key":"1911_CR24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00277-010-0961-x","volume":"89","author":"CF Waller","year":"2010","unstructured":"Waller CF, Bronchud M, Mair S, Challand R (2010) Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:927\u2013933","journal-title":"Ann Hematol"},{"key":"1911_CR25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000319693","volume":"33","author":"CF Waller","year":"2010","unstructured":"Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R (2010) A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 33:504\u2013511","journal-title":"Onkologie"},{"key":"1911_CR26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.critrevonc.2010.01.014","volume":"77","author":"P Gasc\u00f3n","year":"2011","unstructured":"Gasc\u00f3n P, Aapro M, Ludwig H et al (2011) Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol 77:184\u2013197","journal-title":"Crit Rev Oncol Hematol"},{"key":"1911_CR27","doi-asserted-by":"crossref","unstructured":"Tesch H, Indorf M, Schaller-Kranz T. Supportive treatment of chemotherapy-induced neutropenia with biosimilar filgrastim: the HEXAFIL non-interventional study. European Multidisciplinary Cancer Congress (EMCC) 2011; Abstract Book 280: A4025. Available online at: http:\/\/www.ecco-org.eu\/ecco_content\/ECCO16_AbstractBook\/files\/assets\/seo\/page308.html [Accessed 24 August 2012]","DOI":"10.1016\/S0959-8049(11)71268-0"},{"key":"1911_CR28","doi-asserted-by":"crossref","unstructured":"Verpoort K, M\u00f6hler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012, doi: 10.1177\/1758834012461330","DOI":"10.1177\/1758834012461330"},{"key":"1911_CR29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/fon.12.32","volume":"8","author":"N Salesi","year":"2012","unstructured":"Salesi N, Di Cocco B, Colonna M, Veltri E (2012) Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. Future Oncol 8:625\u2013630","journal-title":"Future Oncol"},{"issue":"Suppl 1","key":"1911_CR30","first-page":"S54","volume":"2","author":"MS Rosati","year":"2011","unstructured":"Rosati MS, Baciarello G, Di Seri M, Basile ML, Lo Russo V, Frati L (2011) Biosimilar filgrastim in routine clinical practice: a single centre experience. J Geriatr Oncol 2(Suppl 1):S54, P79","journal-title":"J Geriatr Oncol"},{"key":"1911_CR31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D et al (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337\u2013348","journal-title":"J Manag Care Pharm"},{"key":"1911_CR32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000229504","volume":"77","author":"DV Skarlos","year":"2009","unstructured":"Skarlos DV, Timotheadou E, Galani E et al (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case\u2013control study of the Hellenic Cooperative Oncology Group. Oncology 77:107\u2013112","journal-title":"Oncology"},{"key":"1911_CR33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12325-011-0009-1","volume":"28","author":"F Lefr\u00e8re","year":"2011","unstructured":"Lefr\u00e8re F, Brignier AC, Elie C et al (2011) First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 28:304\u2013310","journal-title":"Adv Ther"},{"key":"1911_CR34","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/bmt.2011.189","volume":"47","author":"JC Ianotto","year":"2012","unstructured":"Ianotto JC, Tempescul A, Yan X et al (2012) Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant 47:874\u2013876","journal-title":"Bone Marrow Transplant"},{"issue":"suppl. 1","key":"1911_CR35","first-page":"S243","volume":"47","author":"A Dmoszynska","year":"2012","unstructured":"Dmoszynska A, Manko J, Croneck AW et al (2012) Comparable efficacy and safety of biosimilar and originator G-CSF in patients undergoing haematopoietic stem cell mobilisation. Bone Marrow Transplant 47(suppl. 1):S243, P700","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"1911_CR36","first-page":"S243","volume":"47","author":"N Yafour","year":"2012","unstructured":"Yafour N, Osmani S, Talhi S et al (2012) Biosimilar G-CSF (filgrastim) is also efficient for peripheral blood stem cell mobilisation and no cryopreserved autologous transplantation. Bone Marrow Transplant 47(Suppl 1):S243, P725","journal-title":"Bone Marrow Transplant"},{"issue":"(suppl 1)","key":"1911_CR37","first-page":"S316","volume":"47","author":"T Czerw","year":"2012","unstructured":"Czerw T, Kruzel T, Sadus-Wojciechowska M et al (2012) Comparison of two formulations of filgrastim, Neupogen (Amgen) and Zarzio (Sandoz), used to accelerate neutrophil recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 47(suppl 1):S316, P872","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"1911_CR38","first-page":"S316","volume":"47","author":"K Kotwica","year":"2012","unstructured":"Kotwica K, Cioch M, Wach M et al (2012) Biosimilar G-CSF is effective in reducing the duration of neutropenia after autologous bone marrow transplantation. Bone Marrow Transplant 47(Suppl 1):S316, P873)","journal-title":"Bone Marrow Transplant"},{"key":"1911_CR39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3324\/haematol.2011.045740","volume":"96","author":"BE Shaw","year":"2011","unstructured":"Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA (2011) Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 96:942\u20137","journal-title":"Haematologica"},{"issue":"suppl 1","key":"1911_CR40","first-page":"S316","volume":"47","author":"N Azar","year":"2012","unstructured":"Azar N, Choquet S, Garnier A et al (2012) Use of a biosimilar G-CSF in allogeneic stem cell mobilisation. Bone Marrow Transplant 47(suppl 1):S316, P727","journal-title":"Bone Marrow Transplant"},{"key":"1911_CR41","unstructured":"Schmitt M, Lena D, Schneider, et al. Use of the G-CSF biosimilar Ratiograstim\u00ae to mobilize peripheral stem cells in healthy donors for allogeneic stem cell transplantation. Abstract presented at the 53rd annual meeting of the American Society of Hematology, December 10\u201313, 2011, San Diego, CA, USA. Available online at: https:\/\/ash.confex.com\/ash\/2011\/webprogram\/Paper38776.html [Accessed 24 August 20120]"},{"issue":"suppl 2s","key":"1911_CR42","first-page":"O177","volume":"48","author":"P Becker","year":"2013","unstructured":"Becker P, Brauninger S, Bialleck H et al (2013) Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: interim results of a post-authorization safety study. Bone Marrow Transplant 48(suppl 2s):O177","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"1911_CR43","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s11523-011-0196-3","volume":"7","author":"P Cornes","year":"2012","unstructured":"Cornes P (2012) The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 7(suppl 1):S57\u2013S67","journal-title":"Target Oncol"},{"key":"1911_CR44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1078155211407367","volume":"18","author":"M Aapro","year":"2012","unstructured":"Aapro M, Cornes P, Abraham I (2012) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 18:171\u2013179","journal-title":"J Oncol Pharm Pract"},{"key":"1911_CR45","unstructured":"IMS Health. MIDAS Global Biologics database, 2012. www.imshealth.com"},{"key":"1911_CR46","doi-asserted-by":"crossref","unstructured":"Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012 Oct 23. doi: 10.1182\/blood-2012-04-425744","DOI":"10.1182\/blood-2012-04-425744"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1911-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1911-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T16:31:15Z","timestamp":1646238675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1911-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1911-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2013,8,1]]}}}